1. FDA Approves Travere's FSGS Drug Despite Lack of Kidney Function Improvement
In a notable regulatory decision, the FDA has approved Travere Therapeutics' drug for the rare kidney disease focal segmental glomerulosclerosis (FSGS), even though the treatment did not demonstrate an improvement in kidney function in its pivotal trial. This approval, for the drug sparsentan (branded as Filspari), mar...